secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2026-07-16T17:56:43+00:00
Accession:  0001663577-26-000218
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.02, 5.03, 7.1, 8.1
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path pivots to crypto treasury, signs LOI with altFINS, and engages Farrington for biotech asset sale
--------------------------------------------------------------------------------

- Raised $28,659 from Reg A sales of 955,300 shares; authorized 5M Series B Preferred shares convertible into 1,000 common each.
- MD Anderson agreed to restart Phase 2 AML trials if Bio-Path pays $292,264 (BP1001) and $63,287 (BP1002) past due.
- Issued 22,342 Series B Preferred for Himalaya Technologies (OTC: HMLA) valued at $670,260, making HMLA a majority-owned subsidiary.
- Engaged Farrington Capital for exclusive out-license/asset sale of DNAbilize platform and all drug programs; 60-day exclusivity.
- Signed LOI with altFINS for Gen2 digital asset treasury; altFINS to receive 2.5M BPTH shares, BPTH gets option to invest €2M at €7.4M valuation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000166357726000218/0001663577-26-000218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000166357726000218/bpth_8k071626.htm
  HTML page:      https://secwatch.observer/filing/0001663577-26-000218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer